BusinessCapricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10By Nasdaq OMXMay 4, 2018, 12:00 PM UTC
BusinessCapricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in MontrealBy Nasdaq OMXMay 3, 2018, 11:01 AM UTC
BusinessCapricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease ModelBy Nasdaq OMXApr 19, 2018, 11:00 AM UTC
BusinessCapricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate UpdateBy Nasdaq OMXMar 14, 2018, 8:00 PM UTC
BusinessCapricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14By Nasdaq OMXMar 8, 2018, 9:00 PM UTC
BusinessNew Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular DystrophyBy Nasdaq OMXFeb 22, 2018, 6:22 PM UTC
BusinessCapricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular DystrophyBy Nasdaq OMXFeb 12, 2018, 1:00 PM UTC
